Hirofumi Ozeki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hirofumi Ozeki has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Ai Hayashi
GlaxoSmithKline K.K., Tokyo, Japan
1 shared publication - Kazuko Suzuki
Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, 2-2-2, Iida-Nishi, Yamagata, 990-9585, Japan
1 shared publication - Masao Yarita
Real World Data Analytics, Japan Development, GSK, Tokyo 107-0052, Japan
1 shared publication - Masashi Takano
Real World Data Analytics, Japan Development, GSK, Tokyo 107-0052, Japan
1 shared publication - Sakiyo Tsukamoto
Medical Affairs, GSK
1 shared publication - Yasuo Nakajima
Medical Affairs, GSK
1 shared publication
Latest Publications
- Open Access
- 3 August 2025
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 41 (8) , 1465-1474
Characteristics and management of patients with renal anaemia treated with daprodustat: an observational study in Japan
HIF-PHI inhibitors, including daprodustat, have expanded treatment options for patients with renal anaemia in Japan. This analysis examines real-world utilization of daprodustat in Japan, for which data are currently lacking. This retrospective cohort study analyzed patient characteristics, treatment patterns, and management of renal anaemia in individuals aged >15 years who were treated with daprodustat between 1 August 2020 and 1 July 2023 using an anonymized electronic medical record database. Patients were assigned to dialysis-dependent (DD) and nondialysis-dependent (ND) cohorts. This study included 1299 patients (111 DD cohort; 1188 ND cohort). Mean age was 71.0 and 79.2 years in the DD and ND cohorts, respectively. In both cohorts, hypertension, heart failure, oesophageal gastric erosion, and type 2 diabetes mellitus were frequent comorbidities. In the DD cohort, 31.5% of patients had Hb levels of 9-10 g/dL at baseline and in the ND cohort 35.9% had Hb levels n = 23; Wilcoxon sign-ranked test [WSRT] p = 0.0148) and from 9.6 g/dL at baseline to 10.4 g/dL in the ND cohort (n = 92; WSRT p < 0.0001) 28 weeks after daprodustat initiation. Approximately a third (DD) to almost half (ND) of patients with renal anaemia were not receiving treatment for anaemia. An increase in haemoglobin levels was observed after initiation of daprodustat, including in patients previously treated with erythropoiesis-stimulating agents, however causality cannot be confirmed due to lack of a control group.
- 3 August 2025
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 41 (8) , 1465-1474
Open AccessCharacteristics and management of patients with renal anaemia treated with daprodustat: an observational study in Japan
HIF-PHI inhibitors, including daprodustat, have expanded treatment options for patients with renal anaemia in Japan. This analysis examines real-world utilization of daprodustat in Japan, for which data are currently lacking. This retrospective cohort study analyzed patient characteristics, treatment patterns, and management of renal anaemia in individuals aged >15 years who were treated with daprodustat between 1 August 2020 and 1 July 2023 using an anonymized electronic medical record database. Patients were assigned to dialysis-dependent (DD) and nondialysis-dependent (ND) cohorts. This study included 1299 patients (111 DD cohort; 1188 ND cohort). Mean age was 71.0 and 79.2 years in the DD and ND cohorts, respectively. In both cohorts, hypertension, heart failure, oesophageal gastric erosion, and type 2 diabetes mellitus were frequent comorbidities. In the DD cohort, 31.5% of patients had Hb levels of 9-10 g/dL at baseline and in the ND cohort 35.9% had Hb levels n = 23; Wilcoxon sign-ranked test [WSRT] p = 0.0148) and from 9.6 g/dL at baseline to 10.4 g/dL in the ND cohort (n = 92; WSRT p < 0.0001) 28 weeks after daprodustat initiation. Approximately a third (DD) to almost half (ND) of patients with renal anaemia were not receiving treatment for anaemia. An increase in haemoglobin levels was observed after initiation of daprodustat, including in patients previously treated with erythropoiesis-stimulating agents, however causality cannot be confirmed due to lack of a control group.